title: Fibroblast growth factor receptor 3 protein expression in urothelial carcinoma of the urinary bladder, exhibiting no association with low-grade and/or non-invasive lesions.
abstract: Activating mutations of fibroblast growth factor receptor 3 (FGFR3), found in autosomal dominant human skeletal dysplasia, were reported to be involved in tumorigenesis and correlate with low-grade and superficial lesions of urothelial carcinoma. FGFR3 protein expression was immunohistochemically investigated in 126 cases of urothelial carcinoma of the urinary bladder to evaluate the role of this receptor in tumor behavior. p53 expression and the proliferating activity of tumor cells, assessed by Ki-67 expression, were also analyzed in parallel. Cytoplasmic and/or membrane immunostaining for FGFR3 was observed in 62 (49.2%) cases, including 20 (15.9%) cases of intense staining and 42 (33.3%) of moderate staining. p53 expression and Ki-67 labeling index (LI) were significantly correlated with high tumor grade (p=0.0093 and <0.0001, respectively) and invasion (p=0.0041 and <0.0001, respectively). Although there were two groups of interesting cases: low-grade and non-invasive tumors negative for p53 but positive for FGFR3, and high-grade and invasive tumors positive for p53 but negative for FGFR3, no statistically significant relationship was found between FGFR3 expression and tumor grade, invasion, p53 expression or Ki-67 LI. These results suggest that FGFR3 protein expression in bladder cancer is unlikely to affect tumor behavior as a unique single factor.
authors.affiliation: Department of Tumor Pathology, Kochi Medical School, Kochi University, Nankoku, Kochi 783-8505, Japan. manabu@med.kochi-u.ac.jp
authors.forename: Manabu
authors.initials: M
authors.lastname: Matsumoto
authors.forename: Yuji
authors.initials: Y
authors.lastname: Ohtsuki
authors.forename: Kenji
authors.initials: K
authors.lastname: Ochii
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Seike
authors.forename: Norihiro
authors.initials: N
authors.lastname: Iseda
authors.forename: Toyokazu
authors.initials: T
authors.lastname: Sasaki
authors.forename: Yuhei
authors.initials: Y
authors.lastname: Okada
authors.forename: Atsushi
authors.initials: A
authors.lastname: Kurabayashi
authors.forename: Mutsuo
authors.initials: M
authors.lastname: Furihata
mesh_terms: D014408:Biomarkers, Tumor / Q000378:metabolism*; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007124:Immunoenzyme Techniques; D019394:Ki-67 Antigen / Q000378:metabolism; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D011505:Protein-Tyrosine Kinases / Q000378:metabolism*; D051498:Receptor, Fibroblast Growth Factor, Type 3; D017468:Receptors, Fibroblast Growth Factor / Q000378:metabolism*; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism; D001749:Urinary Bladder Neoplasms / Q000378:metabolism* / Q000473:pathology
chemical_list: D014408:Biomarkers, Tumor; D019394:Ki-67 Antigen; D017468:Receptors, Fibroblast Growth Factor; D016159:Tumor Suppressor Protein p53; C496365:FGFR3 protein, human; D011505:Protein-Tyrosine Kinases; D051498:Receptor, Fibroblast Growth Factor, Type 3